Stevanato Group S.p.A. has announced the launch of a new proprietary pen injector platform targeting incretin-based therapies, Deora.
The product is a multi-use, fixed-dose pen injector that features a simple pull-push mechanism for dose setting and delivery — the user pulls to set the dose, then pushes to inject.
The company said that the new platform would eliminate the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations.
Deora will be compatible with standard 1.5 mL and 3 mL cartridges and accommodate fixed-dose volumes up to 0.75 mL.
"With Deora, we are broadening our product offering in therapeutic areas experiencing strong global demand and favourable market momentum," said Michele Monico, President of Drug Delivery Systems and In Vitro Diagnostics at Stevanato Group.
We believe there is space for a simple, multi-use device that enhances the patient experience while simultaneously reducing the pressure on supply chain scale-up.
"Our belief has been supported by early customer interest and we are providing our pharmaceutical partners with evaluation units to support early-stage testing and development activities."
The company added that the device's architecture offers flexibility across various fixed-dose configurations while minimising the need for design changes across different variants.
It has also been designed to integrate easily into existing supply chains, facilitating efficient industrialisation and scalable manufacturing.
"Deora further expands Stevanato Group's proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format," added Monico.
Customers can now choose from different hand-held device platforms — Alina, Aidaptus and Deora — to address a broad range of therapeutic needs.
Stevanato Group added in its statement that the new Deora platform utilises its manufacturing capabilities to support future commercialisation.
This positions Deora as a platform to help partners advance early development programmes and prepare for future scaling.